Founded in 1994, Carbon Medical Technologies, Inc. (CMT) is an R&D and manufacturing company that develops implantable medical devices using a proprietary pyrolytic carbon coating technology. CMT has developed multiple FDA approved and CE Marked products, including 20 issued 510(k) premarket notifications. CMT has experience manufacturing, attaining regulatory approval, and divesting or licensing its products to strategic partners.  

CMT has developed a pyrolytic carbon based injectable bulking agent called Durasphere, which is used for the treatment of stress urinary incontinence. Outside of the U.S., the indications for the injectable bulking agent have been expanded to include the treatment of Vesicoureteral Reflux (V.U.R.), Fecal Incontinence, and Gastroesophageal Reflux Disease (GERD). 

The pyrolytic carbon-coating technology is also incorporated into implantable tissue markers developed for biopsy site marking and fiducial markers for radiation therapy treatment planning. The innovative BiomarC Tissue Marking System offers unparalleled flexibility and visibility for precise delineation of biopsy sites.